



ACTAS Dermo-Sifiliográficas

Full English text available at
www.actasdermo.org



BRIEF COMMUNICATION

[Translated article] AEDV BIOBADADERM Registry: 15 Year-Contribution to Psoriasis Therapy Safety

D.P. Ruiz-Genao^{a,*}, A. González-Quesada^b, A. Sahuquillo-Torralba^c, R. Rivera-Díaz^d,
M.A. Descalzo^e, I. García-Doval^f, representing the Biobadaderm Group

^a Servicio de Dermatología, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain

^b Servicio de Dermatología, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain

^c Servicio de Dermatología, Hospital Universitario y Politécnico La Fe, Valencia, Spain

^d Servicio de Dermatología, Hospital Universitario 12 de Octubre, Universidad Complutense, Madrid, Spain

^e Unidad de Investigación, Academia Española de Dermatología y Venereología, Madrid, Spain

^f Servicio de Dermatología, Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain

Received 23 April 2024; accepted 10 November 2024

KEYWORDS

Registries;
Psoriasis;
References as topics;
Safety;
Biological products

PALABRAS CLAVE

Registro;
Psoriasis;
Bibliografía;
Seguridad;
Terapia biológica

Abstract The objective of this article is to collect and describe the most relevant BIOBADADERM findings since its beginning in 2008. BIOBADADERM is a prospective cohort registry whose main aim is to analyze the safety profile of the new systemic therapy for the management of psoriasis. Data included in the registry allowed the publication of numerous articles over the past 15 years (2008–2023). Data from the registry join those obtained from clinical trials regarding safety and efficacy profile. Additionally, it has expanded our knowledge of population groups excluded from clinical trials and in less frequent settings. Collaboration with other registries has given us a few fact-checking answers in smaller groups.

© 2025 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Registro BIOBADADERM de la AEDV: 15 años de aportaciones a la seguridad de los tratamientos para la psoriasis

Resumen El objetivo de este artículo es recopilar y describir los hallazgos más relevantes aportados por BIOBADADERM desde su inicio en 2008. BIOBADADERM es un registro prospectivo de cohortes cuyo objetivo principal es analizar la seguridad de los nuevos tratamientos sistémicos para la psoriasis. El análisis de los datos incluidos en el registro ha permitido la publicación de numerosos artículos en los últimos 15 años (2008–2023), que complementan los ensayos clínicos en cuanto a seguridad y eficacia. Asimismo, ha ampliado los conocimientos

DOI of original article: <https://doi.org/10.1016/j.ad.2024.11.027>

* Corresponding author.

E-mail address: diana@aedv.es (D.P. Ruiz-Genao).

<https://doi.org/10.1016/j.ad.2025.05.012>

0001-7310/© 2025 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Please cite this article as: D.P. Ruiz-Genao, A. González-Quesada, A. Sahuquillo-Torralba et al., [Translated article] AEDV BIOBADADERM Registry: 15 Year-Contribution to Psoriasis Therapy Safety, ACTAS Dermo-Sifiliográficas, <https://doi.org/10.1016/j.ad.2025.05.012>

en grupos poblacionales excluidos de los ensayos clínicos y en escenarios poco frecuentes. La colaboración con otros registros nos ha permitido dar respuesta a preguntas sobre grupos menos frecuentes.

© 2025 AEDV. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

In 2008, the Psoriasis Working Group of the Spanish Academy of Dermatology and Venereology, in collaboration with the Spanish Agency for Medicines and Health Products and the Spanish Foundation of Rheumatology, launched the BIOBADADERM registry.¹ As of November 2023, it included a total of 21 participant hospitals, 6000 psoriatic patients on systemic therapy, and almost 30,000 patient-years of follow-up in a prospective cohort. Data quality is checked through periodic monitoring. Its main objective is to analyze the safety profile of new systemic therapies for psoriasis.

With 15 years of evolution, BIOBADADERM is probably the longest-running scientific project of the AEDV. The objective of this article is to compile its most relevant scientific contributions for daily clinical practice. Table 1 groups the articles by topic.

Data on new drugs come primarily from clinical trials and experience in other diseases, but, as BIOBADADERM has demonstrated, these data are not always generalizable to the psoriatic population.

In the field of safety, data extrapolation from other diseases has clear limitations. BIOBADADERM has analyzed the mid- and long-term adverse events (AEs) of recently marketed drugs, with results supporting their safety profile in the routine clinical practice. In addition, comparative studies of different drugs facilitate therapeutic selection. Of note, the occurrence of AEs in the registry is not the same at all times during therapy. They are more frequent within year 1, especially with systemic treatments, while the risk of serious AEs remains constant over time. Notifications of unknown adverse effects are essential for the continuous evaluation of drug safety. BIOBADADERM has detected an alert regarding symptomatic urinary tract infection with cyclosporine, infliximab, and anti-IL17 drugs, and data have supported the hypothesis that anti-TNF drugs and ustekinumab can infrequently induce paradoxical arthritis after several months into therapy.

During the COVID-19 pandemic, suspicion abounded on the safety of drugs used daily in the treatment of psoriasis. Having an active registry made it possible to conclude that

neither classic nor biological drugs increase the susceptibility or severity of COVID-19 infection.

The increasing availability of safe and effective drugs has changed the therapeutic approach to psoriasis, with biologics being used more and more frequently. In addition, the biological drug prescribed first has changed over time, and in participating hospitals, the use of biologics at different doses than recommended is common. In clinical practice, variable dosage has numerous advantages, such as individual adaptation, reduction of side effects, economic optimization, and greater flexibility. BIOBADADERM has confirmed the safety of these drugs in various day-to-day situations, such as surgery or their use as first-line therapy.

Regarding associated comorbidities, we have found that an increase in body mass index is associated with a higher risk of treatment discontinuation due to lack of efficacy and with an increased risk of AEs. Similarly, patients with psoriatic arthritis had a higher number of comorbidities, especially hypertension and liver disease, used a greater number of treatments, and exhibited more AEs and infections/infestations regardless of associated comorbidities and current or past treatments.

One of the measurements used to indirectly assess the safety and efficacy profile of a drug is survival, defined as the duration of a specific therapy. However, after analyzing the survival of different biologics and systemic drugs in the registry, we have concluded that survival is not adequate as a measure of safety (and probably effectiveness), especially when comparing different drugs. This is due to the number of factors that can influence survival independent of safety or efficacy.

The possibility of identifying prognostic factors that help us predict treatment response is an interesting question. Patients with fewer previous treatments, who are thinner, older at the start of treatment, and with a previous history of good response have had a higher probability of obtaining good results.

Data obtained from the registries on epidemiology, comorbidities, and management provide valuable information on rare clinical forms. The number of cases of erythrodermic psoriasis included in BIOBADADERM has gradually decreased at the follow-up, which may reflect better disease control and supports the idea that EP in some patients is a severe stage of other types of psoriasis. Patients with generalized pustular psoriasis had a higher prevalence of kidney and liver disease, while patients with palmoplantar pustulosis showed a higher risk of hypercholesterolemia. These previously undescribed findings should be taken considered in the routine clinical practice.

Table 1 Theme-based bibliographic references.

Topic	References
External validity of studies	2–4
Safety data	5–18
Clinical practice	19–26
Clinical presentations	27,28
Special populations	29–35
International cooperation	36–40

BIOBADADERM includes a more diverse and representative population as it does not have inclusion and exclusion criteria as strict as those in clinical trials.

After analyzing the differences by sex, women were more likely to receive a biological drug. No sex differences were detected in terms of efficacy, but women had a higher risk of developing AEs. Women of childbearing age showed a reduction in fertility rate. The only significant variables related were age and disease duration. The review of pregnancies and experience in women with inflammatory bowel disease indicated a probable low risk of complications. A striking decrease in the percentage of breastfeeding has been observed, probably due to psoriasis outbreaks.

The different age groups have also been studied. Those younger than 21 years represented a very small group. These data could reflect a lower disease burden or undertreatment, delaying the initiation of systemic treatment until adulthood. Patients were more frequently managed with classic treatments, and the average age at the start of classic or biological systemic treatment in those younger than 18 years was 14.5 years. In the elderly, the use of biologics was associated with a lower risk of AEs in young and old patients. Serious AEs were more common in elderly patients, but may be related to other particularities of the group and not be directly due to the drug used.

The management of patients with human immunodeficiency virus (HIV) is controversial and limited. BIOBADADERM analyzed 23 HIV-positive patients followed for an average of 3.2 years. Anti-TNF drugs and ustekinumab were effective and safe in combination with adequate antiviral therapy.

BIOBADADERM is part of Psonet (network of independent European registries of patients with psoriasis and PsA on systemic therapy), which has not detected an increased risk of cancer in the mid-term, although data heterogeneity and methodological limitations did not allow ruling out a small increased risk of some tumor subtypes. Similarly, in the routine clinical practice, anti-TNFs for psoriasis have not been associated with a significantly increased risk of serious infections compared to classic treatments.

The analysis of prescription trends in different countries has observed large differences in the use of drugs, especially in terms of availability and management, with variability between countries in the distribution of covariates that potentially influence the choice of treatment (e.g., age, PASI, proportion of patients with psoriasis vulgaris vs other forms of psoriasis). Some variables were directly related to the chances of receiving a biological or a systemic drug in most registries (BMI, PsA, psoriatic onychopathy, or proportion of current smokers).

Psonet data from Spain, France, and the United Kingdom are being analyzed in a global study comparing the survival and safety of biosimilar adalimumab versus the original. The results are still pending publication.

In conclusion, BIOBADADERM, as a prospective cohort focused on describing drug safety, has provided data that complement the knowledge generated by clinical trials, especially in special populations or those not included in them, in infrequent exposures and outcomes such as drug combinations or long-term effects, and in risks of late onset. Collaboration with other registries has allowed us to answer questions about less frequent groups.

Funding

The BIOBADADERM project was promoted by *Fundación Piel Sana* of the Spanish Academy of Dermatology and Venereology and is funded by the Spanish Agency for Medicines and Health Products (AEMPS) and pharmaceutical companies, such as AbbVie, Almirall, Amgen, Boehringer Ingelheim, BMS, Janssen, and UCB. The following companies have also collaborated in the past (Biogen, Leo Pharma, Lilly, MSD, Novartis, and Pfizer).

The collaborating pharmaceutical companies did not participate in the design or the study; nor in the collection, management, analysis, and interpretation of data, or in the preparation, review, or approval of the manuscript and the decision to submit the manuscript for publication.

Conflict of interests

None declared.

Acknowledgments

BIOBADADERM Group, Andrea Montes Torres, Beatriz González Sixto.

References

1. Rivera R, García-Doval I, Carretero G, Daudén E, Sánchez-Carazo J, Ferrándiz C, et al. BIOBADADERM: registro español de acontecimientos adversos de terapias biológicas en dermatología. Primer informe. *Actas Dermosifiliogr.* 2011;102:132–41.
2. García-Doval I, Carretero G, Vanaclocha F, Ferrándiz C, Daudén E, Sánchez-Carazo JL, et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs. eligible for randomized controlled trials. *Arch Dermatol.* 2012;148:463–70.
3. García-Doval I, Hernández MV, Vanaclocha F, Sellas A, de la Cueva P, Montero D, et al. Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts. *Br J Dermatol.* 2017;176:643–9.
4. Carrascosa JM, García-Doval I, Pérez-Zafra B, Carretero G, Vanaclocha F, Daudén E, et al. Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: a cross-sectional study in clinical practice. *J Dermatol Treat.* 2015;26:502–6.
5. Carretero G, Ferrándiz G, Daudén E, Vanaclocha F, Gómez-García FJ, Herrera-Ceballos E, et al. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008–2013 results of the Biobadaderm registry. *J Eur Acad Dermatol Venereol.* 2015;29:156–63.
6. Belinchon I, Ramos JM, Carretero G, Ferrándiz C, Rivera R, Daudén E, et al. Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry Biobadaderm. *J Eur Acad Dermatol Venereol.* 2017;31:1700–8.
7. Lluch-Galcera JJ, Carrascosa JM, González-Quesada A, Rivera-Díaz R, Sahuquillo-Torralba A, Llamas-Velasco M, et al. Safety of biologic therapy in combination with methotrexate in mod-

- erate to severe psoriasis: a cohort study from the BIOBADADERM registry. *Br J Dermatol*. 2023;ljad382.
8. Davila-Seijo P, Dauden E, Descalzo MA, Carretero G, Carrascosa JM, Vanaclocha F, et al. Infections in moderate to severe psoriasis patients treated with biological drugs compared to classic systemic drugs: Findings from the BIOBADADERM Registry. *J Invest Dermatol*. 2017;137:313–21.
 9. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, 2000 BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. *Arthritis Rheum*. 2003;48:2122–7.
 10. Sanchez-Moya AI, Garcia-Doval I, Carretero G, Sanchez-Carazo J, Ferrándiz C, Herrera Ceballos E, et al. Latent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain. *J Eur Acad Dermatol Venereol*. 2013;27:1366–74.
 11. Sanz-Bueno J, Vanaclocha F, García-Doval I, Torrado R, Carretero G, Daudén E, et al. Risk of reactivation of hepatitis B virus infection in psoriasis patients treated with biologics: a retrospective analysis of 20 cases from the BIOBADADERM Database. *Actas Dermosifiliogr*. 2015;106:477–82.
 12. Descalzo MA, Carretero G, Ferrándiz C, Rivera R, Daudén E, Gómez-García FJ, et al. Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: a cohort study. *J Am Acad Dermatol*. 2018;78:798–800.
 13. Dauden E, Carretero G, Rivera R, Ferrándiz C, Llamas-Velasco M, de la Cueva P, et al. Long-term safety of nine systemic medications for psoriasis: a cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry. *J Am Acad Dermatol*. 2020;83:139–50.
 14. Belinchon I, Ramos JM, Carretero G, Ferrándiz C, Rivera R, Dauden E, et al. Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry Biobadaderm. *J Eur Acad Dermatol Venereol*. 2017;31:1700–8.
 15. Munera-Campos M, Baniandrés-Rodríguez O, Vilar-Alejo J, Rivera R, Carrascosa JM, Daudén E, et al. The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry. *J Dermatolog Treat*. 2022;33:2110–7.
 16. Baniandrés-Rodríguez O, Vilar-Alejo J, Rivera R, Carrascosa JM, Daudén E, Herrera-Acosta E, et al. Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: a Biobadaderm cohort analysis. *J Am Acad Dermatol*. 2021;84:513–7.
 17. Sahuquillo-Torralba A, Carretero G, Rivera R, Ferrándiz C, Daudén-Tello E, de la Cueva P, et al. The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: a prospective cohort study. *J Am Acad Dermatol*. 2020;82:738–41.
 18. Ruiz-Genao D, Perez-Zafrilla B, Lopez-Estebarez JL, Belinchon-Romero I, Carrascosa JM, Ferran M, et al. Possible paradoxical occurrence of inflammatory arthritis in patients with psoriasis treated with biologics: findings in the Biobadaderm cohort. *Br J Dermatol*. 2017;176:797–9.
 19. Carrascosa JM, Rivera R, Garcia-Doval I, Carretero G, Vanaclocha F, Daudén E, et al. Escalera terapéutica en la psoriasis moderada y grave. ¿Solo hacia arriba? El porcentaje de pacientes con psoriasis grave tratados con biológicos se incrementa con el tiempo. *Actas Dermosifiliogr*. 2015;106:638–43.
 20. Ruiz-Genao DP, Carretero G, Rivera R, Ferrándiz C, Daudén E, de la Cueva P, et al. Changing trends in drug prescription and causes of treatment discontinuation of first biologic over ten years in psoriasis in the Spanish Biobadaderm Registry. *Actas Dermosifiliogr (Engl Ed)*. 2020;111:752–60.
 21. Galiano Mejías S, Carretero G, Ferrándiz C, Vanaclocha F, Dauden E, Gomez-Garcia FJ, et al. Manejo de los tratamientos biológicos en pacientes con psoriasis moderada-severa tratados mediante intervenciones quirúrgicas en el registro español BIOBADADERM. *Actas Dermosifiliogr*. 2017;108:52–8.
 22. Carretero Hernández G, Ferrándiz C, Rivera Díaz R, Daudén Tello E, de la Cueva-Dobao P, Gómez-García FJ, et al. Description of patients treated with biologic drugs as first-line systemic therapy in the BIOBADADERM registry between 2008 and 2016. *Actas Dermosifiliogr (Engl Ed)*. 2018;109:617–23.
 23. García-Doval I, Pérez-Zafrilla B, Ferrándiz C, Carretero G, Daudén E, de la Cueva P, et al. Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the Biobadaderm cohort. *J Dermatol Treat*. 2016;27:203–9.
 24. Carrascosa JM, Vilavella M, Garcia-Doval I, Carretero G, Vanaclocha F, Dauden E, et al. Body Mass Index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal. Results of the Biobadaderm Registry. *J Eur Acad Dermatol Venereol*. 2014;28:907–14.
 25. Perez-Plaza A, Carretero G, Ferrándiz C, Vanaclocha F, Gomez-Garcia FJ, Herrera-Ceballos E, et al. Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. *Biobadaderm registry*. *J Eur Acad Dermatol Venereol*. 2017;31:1021–8.
 26. Davila-Seijo P, Dauden E, Carretero G, Ferrándiz C, Vanaclocha F, Gomez-Garcia FJ, et al. Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis. *J Eur Acad Dermatol Venereol*. 2016;30:1942–50.
 27. Rivera-Díaz R, Carretero G, Carrascosa JM, Garcia-Doval I. Erythrodermic psoriasis has become less frequent: results from the Biobadaderm Registry. *Actas Dermosifiliogr*. 2023;114:366–9.
 28. Ruiz Genao DP, Carretero G, Rivera-Díaz R, Carrascosa JM, Sahuquillo-Torralba A, Herrera-Acosta E, et al. Differences in epidemiology, comorbidities and treatment choice between plaque psoriasis and pustular psoriasis: results from the BIOBADADERM registry. *Br J Dermatol*. 2022;187:817–20.
 29. Hernández-Fernández CP, Carretero G, Rivera R, Ferrándiz C, Daudén E, de la Cueva P, et al. Effect of sex in systemic psoriasis therapy: differences in prescription effectiveness and safety in the BIOBADADERM Prospective Cohort. *Acta Derm Venereol*. 2021;101, adv00354.
 30. Gonzalez-Cantero A, Carretero G, Rivera R, Ferrándiz C, Daudén E, de la Cueva P, et al. Women with moderate-to-severe psoriasis in Spain (BIOBADADERM registry) show more than a 50% reduction in age-adjusted fertility rate when compared with the general population. *Br J Dermatol*. 2019;181:1085–7.
 31. Echeverría-García B, Nuno-Gonzalez A, Dauden E, Vanaclocha F, Torrado R, Belinchon I, et al. Serie de casos de pacientes psoriásicas expuestas a terapia biológica durante el embarazo Registro BIOBADADERM y revisión de la literatura. *Actas Dermosifiliogr*. 2017;108:168–70.
 32. Rivera-Díaz R, Llamas-Velasco M, Carretero G, Ruiz-Genao D, Belinchón I, Riera-Monroig J, et al. Women with moderate-to-severe psoriasis in Spain (BIOBADADERM registry) breastfeed less when compared with general population. *J Eur Acad Dermatol Venereol*. 2022;36:e205–7.
 33. Nieto Benito LM, Carretero G, Rivera-Díaz R, Carrascosa JM, Daudén E, de la Cueva P, et al. Moderate to severe psoriasis in pediatric and young patients: the BIOBADADERM Registry Experience. *Actas Dermosifiliogr*. 2022;113:401–6.
 34. Medina C, Carretero G, Ferrándiz C, Dauden E, Vanaclocha F, Gomez-Garcia FJ, et al. Safety of classic and biologic systemic

- therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry. *J Eur Acad Dermatol Venereol*. 2015;29:858–64.
35. Montes-Torres A, Aparicio G, Rivera R, Vilarrasa E, Marcellán M, Notario J, et al. Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study. *J Dermatolog Treat*. 2019;30:461–5.
36. Garcia-Doval I, Descalzo MA, Mason KJ, Cohen AD, Ormerod AD, Gómez-García FJ, et al. Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy Spain, the U.K. and Republic of Ireland. *Br J Dermatol*. 2018;179:863–71.
37. Garcia-Doval I, Cohen AD, Cazzaniga S, Feldhamer I, Addis A, Carretero G, et al. Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: prospective meta-analysis of Psonet registries. *J Am Acad Dermatol*. 2017;76:299–308.
38. Garcia-Doval I, Rustenbach SJ, Stern R, Dam TN, Cohen AD, Baker C, et al. Systemic psoriasis therapy shows high between-countries variation. A sign of unwarranted variation? Cross-sectional analysis of baseline data from the Psonet registries. *Br J Dermatol*. 2013;169:710–4.
39. Davila-Seijo P, Garcia-Doval I, Naldi L, Cazzaniga S, Augustin M, Rustenbach SJ, et al. Factors associated with receiving biologics or classic systemic therapy for moderate-to-severe psoriasis: evidence from the PSNET Registries. *Acta Derm Venereol*. 2017;97:516–8.
40. Phan DB, Jourdain H, González-Quesada A, Zureik M, Rivera-Díaz R, Sahuquillo-Torralba A, et al. Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study. *BMJ Open*. 2023;13:e075197.